Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline
Open accessThe DOI matches its Crossref record; 152 of the 154 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To formulate clinical practice guidelines for the pharmacological management of obesity. PARTICIPANTS: An Endocrine Society-appointed Task Force of experts, a methodologist, and a medical writer. This guideline was co-sponsored by the European Society of Endocrinology and The Obesity Society. EVIDENCE: This evidence-based guideline was developed using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system to describe the strength of recommendations and the quality of evidence. CONSENSUS PROCESS: One group meeting, several conference calls, and e-mail communications enabled consensus. Committees and members of the Endocrine Society, the European Society of Endocrinology, and The Obesity Society reviewed and commented on preliminary drafts of these guidelines. Two systematic reviews were conducted to summarize some of the supporting evidence. CONCLUSIONS: Weight loss is a pathway to health improvement for patients with obesity-associated risk factors and comorbidities. Medications approved for chronic weight management can be useful adjuncts to lifestyle change for patients who have been unsuccessful with diet and exercise alone. Many medications commonly prescribed for diabetes, depression, and other chronic diseases have weight effects, either to promote weight gain or produce weight loss. Knowledgeable prescribing of medications, choosing whenever possible those with favorable weight profiles, can aid in the prevention and management of obesity and thus improve health.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“In contrast, the National Institute for Health and Clinical Excellence (NICE) [37], Endocrine Society [35], and American College of Cardiology [36] uniformly recommend using only licensed medications for weight management and did not consider off-label options such as metformin.”
From A systematic review of licensed weight-loss medications in treating antipsychotic-induced weight gain and obesity in schizophrenia and psychosis. (2022) · cites this paper as [35]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The STEP 1, 3, and 4 trials used semaglutide in conjunction with a lifestyle program and resulted in 16.9% to 18.2% weight-loss (using a completers-type analysis), which is superior to phase 3 trial results for other weight-loss medications, though without head-to-head drug comparison.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [759]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Commonly prescribed medications such as antidepressants (eg, mirtazapine, amitriptyline) and antihyperglycemics such as glyburide or insulin cause weight gain, and clinicians should review and consider alternatives.”
From Obesity Management in Adults: A Review (2023) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Consideration of individual food preferences, cultural traditions, and budgetary requirements may aid in the adherence to healthy dietary patterns, a key predictor of success [42,45].”
From Nutritional considerations with antiobesity medications (2024) · cites this paper as [42]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Medication classes promoting weight gain include antihyperglycemics (eg, glyburide, insulin), antidepressants (eg, amitriptyline, mirtazapine), antipsychotics (eg, olanzapine, quetiapine), antiepileptics (eg, gabapentin, carbamazepine), β-blockers, progesterone-based contraceptives, corticosteroids, and antiretroviral therapy (eg, protease inhibitors).12,77”
From Obesity Management in Adults: A Review (2023) · cites this paper as [12]
Experimental — accuracy not yet measured
29 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873 · cited 1×
“The AHA/ ACC/TOS Guideline for the Management of Overweight and Obesity in Adults reviewed randomized clinical trials on weight loss interventions and determined that the best weight loss outcomes occur with frequent face-to-face visits (16 visits per year on average) (8, 38).”
BackgroundGrading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477 · cited 1×
“The Task Force followed the approach recommended by the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) group, an international group with expertise in the development and implementation of evidence-based guidelines (1).”
MethodOverweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. Adults
Calle, E. E., Rodriguez, C., Walker-Thurmond, K., & Thun, M. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021423 · Cited by 7,696 · cited 1×
“obese are at increased risk for many malignancies (7).”
BackgroundDecision aids for people facing health treatment or screening decisions
Stacey, D., Légaré, F., Lewis, K., Barry, M. J., Bennett, C. L., Eden, K. B., Holmes-Rovner, M., Llewellyn-Thomas, H., Lyddiatt, A., Thomson, R., et al. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001431.pub5 · Cited by 6,685
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults
Jensen, M. D., Ryan, D. H., Apovian, C. M., Ard, J. D., Comuzzie, A. G., Donato, K. A., Hu, F. B., Hubbard, V. S., Jakicic, J. M., Kushner, R. F., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.004 · Cited by 4,058
Self-citationNathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Weight and Type 2 Diabetes after Bariatric Surgery: Systematic Review and Meta-analysis
Buchwald, H., Estok, R., Fahrbach, K., Banel, D., Jensen, M. D., Pories, W. J., Bantle, J. P., & Sledge, I. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2008.09.041 · Cited by 2,551 · cited 1×
“T2DM Yes Cohen, 2012 (132); Mingrone, 2012 (133); Schauer, 2012 (134); Buchwald, 2009 (135) Hypertension Yes Ilane-Parikka, 2008 (136); Phelan, 2007 (137); Zanella, 2006 (138) Dyslipidemia and metabolic syndrome Yes Ilane-Parikka, 2008 (136); Phelan, 2007 (137); Zanella, 2006 (138) Cardiovascular disease Yes Wannameth…”
Central nervous system control of food intake and body weight
Morton, G. J., Cummings, D. E., Baskin, D. G., Barsh, G. S., & Schwartz, M. W. (2006) · Nature · doi:10.1038/nature05026 · Cited by 2,503 · cited 1×
“GLP-1 agonists also affect the POMC neurons and cause satiety (18).”
Background
Research works printed but not linked: 15
- [3]3. DomecqJP,PrutskyG,LeppinA,etal. Drugscommonlyassociated with weight change: a systematic review and meta-analysis. J Clin Endocrinol Metab . 2015;100:363-370.
- [11]11. Goldsmith R, Joanisse DR, Gallagher D, et al. Effects of experimentalweightperturbationonskeletalmuscleworkefficiency,fuel utilization, and biochemistry in human subjects. Am J Physiol Regul Integr Comp Physiol . 2010;298:R79-R88.
- [19]19. Stahl SM. Impulsivity, compulsivity, and addiction. In: Stahl's Essential Psychopharmacology . 4th ed. New York, NY: Cambridge University Press; 2013:537-575.
- [22]22. Mendieta-ZerónH,LópezM,DiéguezC. Gastrointestinalpeptides controlling body weight homeostasis. Gen Comp Endocrinol . 2008;155:481-495.
- [35]35. Avenell A, Brown TJ, McGee MA, et al. Whatinterventions should weaddtoweightreducingdietsinadultswithobesity?Asystematic review of randomized controlled trials of adding drug therapy, exercise, behaviourtherapyorcombinationsoftheseinterventions. J Hum Nutr Diet . 2004;17:293-316.
- [68]68. Grandy S, Hashemi M, Langkilde AM, Parikh S, Sjöström CD. Changesinweightloss-related quality of life among type 2 diabetes mellitus patients treated with dapagliflozin. Diabetes Obes Metab . 2014;16:645-650.
- [79]79. Greenway FL, Fujioka K, Plodkonski RA, et al. COR I Study Group. Lancet . 2010;376:595-605.
- [82]82. Jacob AN, Salinas K, Adams-Huet B, Raskin P. Weightgainintype 2 diabetes mellitus. Diabetes Obes Metab . 2007;9:386-393.
- [88]88. Mäkimattila S, Nikkilä K, Yki-Järvinen H. Causes of weight gain duringinsulintherapywithandwithoutmetformininpatientswith type II diabetes mellitus. Diabetologia . 1999;42:406-412.
- [95]95. WingLM,ReidCM,RyanP,etal. Acomparisonofoutcomeswith angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med . 2003;348:583-592.
- [110]110. MaayanL,CorrellCU. Weightgainandmetabolicrisks associated withantipsychoticmedicationsinchildrenandadolescents. J Child Adolesc Psychopharmacol . 2011;21:517-535.
- [126]126. Boers M, van der Heijde DM. Prevention or retardation of joint damageinrheumatoidarthritis:issuesofdefinition,evaluationand interpretation of plain radiographs. Drugs . 2002;62(12):17171724.
- [128]128. Aronne LJ. Drug-induced weight gain: non-CNS medications. In: Aronne LJ, ed. A Practical Guide to Drug-Induced Weight Gain . Minneapolis, MN: McGraw-Hill; 2002:77-91.
- [14]14. tional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study. Am J Gastroenterol . 2005;100:1072-1081.
- [146]146. Huang MH, Chen CH, Chen TW, Weng MC, Wang WT, Wang YL. Theeffectsofweightreductionontherehabilitationofpatients with knee osteoarthritis and obesity. Arthritis Care Res . 2000;13: 398-405.
Cited by
Items 101–200 of 1,001
Clinical Considerations Regarding the Use of Obesity Pharmacotherapy in Adolescents with Obesity
Srivastava, G., Fox, C. K., Kelly, A. S., Jastreboff, A. M., Browne, A. F., Browne, N. T., Pratt, J. S. A., Bolling, C., Michalsky, M. P., Cook, S., et al. (2019) · Obesity · doi:10.1002/oby.22385 · Cited by 130
“This algorithm is consistent with adult and pediatric guidelines that recommend discontinuation of an obesity medication, at maximum appropriate dose, if less than 5% weight loss/ BMI reduction from baseline is achieved within 12 weeks (60-62).”
MethodSelf-citationWadden, T. A., Chao, A. M., Moore, M., Tronieri, J. S., Gilden, A., Amaro, A., Leonard, S., & Jakicic, J. M. (2023) · Current Obesity Reports · doi:10.1007/s13679-023-00534-z · Cited by 129
“…the weight loss, on average, as traditional lifestyle modification and also represented a major advancement over the four previously approved medications for chronic weight management—orlistat, naltrexone-bupropion extended release (ER), phentermine-topiramate ER, and liraglutide 3.0 mg [37–39].”
BackgroundInfluentialA comprehensive diagnostic approach to detect underlying causes of obesity in adults
van der Valk, E. S., van den Akker, E. L. T., Savas, M., Kleinendorst, L., Visser, J. A., Van Haelst, M. M., Sharma, A. M., & van Rossum, E. F. C. (2019) · Obesity Reviews · doi:10.1111/obr.12836 · Cited by 129
“Although most prescribers are aware of these side effects, in patients with severe obesity, a medication switch to less obesogenic drugs should be considered if possible.(38) It is well‐known that systemic corticosteroids can cause weight gain.”
BackgroundInfluentialGomez, G., & Stanford, F. C. (2018) · International Journal of Obesity · doi:10.1038/ijo.2017.287 · Cited by 128
National lipid association annual summary of clinical lipidology 2016
Bays, H. E., Jones, P. H., Orringer, C. E., Brown, W. V., & Jacobson, T. A. (2016) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2015.08.002 · Cited by 128
Thomas, C. E., Mauer, E. A., Shukla, A. P., Rathi, S., & Aronne, L. J. (2016) · Obesity · doi:10.1002/oby.21533 · Cited by 124
“In February 2015, The Endocrine Society issued clinical practice guidelines on the pharmacological management of obesity (15).”
BackgroundSelf-citationA Review on Role of Microbiome in Obesity and Antiobesity Properties of Probiotic Supplements
Sivamaruthi, B. S., Kesika, P., Suganthy, N., & Chaiyasut, C. (2019) · BioMed Research International · doi:10.1155/2019/3291367 · Cited by 124
Grams, J. M., & Garvey, W. T. (2015) · Current Obesity Reports · doi:10.1007/s13679-015-0155-x · Cited by 146
de Frel, D. L., Atsma, D. E., Pijl, H., Seidell, J. C., Leenen, P. J. M., Dik, W. A., & van Rossum, E. F. C. (2020) · Frontiers in Nutrition · doi:10.3389/fnut.2020.597600 · Cited by 155
Shared decision making in endocrinology: Present and future directions
Rodriguez-Gutierrez, R., Gionfriddo, M. R., Ospina, N. S., Maraka, S., Tamhane, S., Montori, V. M., & Brito, J. P. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00468-4 · Cited by 117
Wadden, T. A., Walsh, O. A., Berkowitz, R. I., Chao, A. M., Alamuddin, N., Gruber, K., Leonard, S., Mugler, K., Bakizada, Z., & Tronieri, J. S. (2019) · Obesity · doi:10.1002/oby.22359 · Cited by 116
“Medications for chronic weight management offer a second option for inducing a 5% or greater loss (7,8).”
BackgroundPharmacotherapy for the management of obesity
Patel, D. K. (2015) · Metabolism · doi:10.1016/j.metabol.2015.08.001 · Cited by 130
“depression, and arthritis may often lead to significant weight gain [16].”
BackgroundMethodInfluentialUpdates on obesity pharmacotherapy
Velazquez, A., & Apovian, C. M. (2018) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13542 · Cited by 115
Self-citationLong-term effects of weight-reducing drugs in people with hypertension
Siebenhofer, A., Jeitler, K., Horvath, K., Berghold, A., Posch, N., Meschik, J., & Semlitsch, T. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007654.pub4 · Cited by 104
Pharmacological management of nonalcoholic fatty liver disease
Barb, D., Portillo-Sanchez, P., & Cusi, K. (2016) · Metabolism · doi:10.1016/j.metabol.2016.04.004 · Cited by 114
Ramseier, C. A., Woelber, J. P., Kitzmann, J., Detzen, L., Carra, M. C., & Bouchard, P. (2020) · Journal Of Clinical Periodontology · doi:10.1111/jcpe.13240 · Cited by 136
Liu, Y., Ruan, B., Jiang, H., Le, S., Liu, Y., Ao, X., Huang, Y., Shi, X., Xue, R., Fu, X., et al. (2023) · The American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2023.04.017 · Cited by 110
Cardiometabolic-Based Chronic Disease, Addressing Knowledge and Clinical Practice Gaps
Mechanick, J. I., Farkouh, M. E., Newman, J. D., & Garvey, W. T. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.11.046 · Cited by 113
Herbal Medicine for the Treatment of Obesity: An Overview of Scientific Evidence from 2007 to 2017
Liu, Y., Sun, M., Yao, H., Liu, Y., & Gao, R. (2017) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2017/8943059 · Cited by 131
“Obesity drugs can be divided into five categories: central appetite suppressants, digestion and absorption blockers, metabolic promoters, obesity gene product inhibitors, and other drugs for the treatment of obesity [9].”
BackgroundAras, M., Tchang, B. G., & Pape, J. (2021) · Nursing Clinics of North America · doi:10.1016/j.cnur.2021.07.008 · Cited by 108
Lewis, K. H., Fischer, H., Ard, J., Barton, L., Bessesen, D. H., Daley, M. F., Desai, J., Fitzpatrick, S. L., Horberg, M., Koebnick, C., et al. (2019) · Obesity · doi:10.1002/oby.22430 · Cited by 110
“Pharmacotherapy can increase the proportion of individuals who respond to lifestyle interventions as well as the duration and magnitude of response (6).”
BackgroundSelf-citationGiagulli, V. A., Carbone, M. D., Ramunni, M. I., Licchelli, B., De Pergola, G., Sabbà, C., Guastamacchia, E., & Triggiani, V. (2015) · Andrology · doi:10.1111/andr.12099 · Cited by 109
“, 2015) and by obesity [body mass index (BMI) >30 kg/m(2)) (Apovian et al., 2015; Handelsman et al., 2015).”
BackgroundMethodInfluentialStrategies to Treat Obesity in Patients With CKD
Chintam, K., & Chang, A. R. (2020) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2020.08.016 · Cited by 118
“There are several medication classes that contribute to weight that deserve mention, including some diabetes medications, atypical antipsychotics, corticosteroids and hormone replacement therapy, antiepileptic medications, antidepressants, antihistamines, and betablockers (63).”
BackgroundLundkvist, P., Sjöström, C. D., Amini, S., Pereira, M. J., Johnsson, E., & Eriksson, J. W. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12779 · Cited by 108
“The management of obesity is challenging; dietary and lifestyle interventions are difficult to sustain,(2,3) and pharmacotherapies for obesity have generally been ineffective over time, often with troublesome side effects.(4) In contrast to older glucose-lowering medications (sulphonylureas, insulin, thiazolidinedione…”
BackgroundClinical practice guidelines in China
Chen, Y., Wang, C., Shang, H., Yang, K., & Norris, S. L. (2018) · BMJ · doi:10.1136/bmj.j5158 · Cited by 108
GLP-1 Receptor Agonists and Cancer Risk in Adults With Obesity
Dai, H., Li, Y., Lee, Y. A., Lu, Y., George, T. J., Donahoo, W. T., Lee, K. P., Nakshatri, H., Allen, J. M., Guo, Y. M., et al. (2025) · JAMA Oncology · doi:10.1001/jamaoncol.2025.2681 · Cited by 135
Hollander, P., Bays, H. E., Rosenstock, J., Frustaci, M. E., Fung, A., Vercruysse, F., & Erondu, N. (2017) · Diabetes Care · doi:10.2337/dc16-2427 · Cited by 106
Guan, Y., Wang, D., Bu, H., Zhao, T., & Wang, H. (2020) · International Journal of Endocrinology · doi:10.1155/2020/5150684 · Cited by 106
“Our current results suggest thatmetforminmay be themost effective intervention for PCOS in overweight women [47].”
ResultReward-Induced Eating: Therapeutic Approaches to Addressing Food Cravings
Rebello, C. J., & Greenway, F. L. (2016) · Advances in Therapy · doi:10.1007/s12325-016-0414-6 · Cited by 105
“Phentermine (common brand names Adipex-P, Ionamin) is primarily a noradrenergic and perhaps dopaminergic sympathomimetic amine that acts as an appetite suppressant [64].”
BackgroundThe Beige Adipocyte as a Therapy for Metabolic Diseases
Lizcano, F. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20205058 · Cited by 118
Approach to Obesity Treatment in Primary Care: A Review
Yanovski, S. Z., & Yanovski, J. A. (2024) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2023.8526 · Cited by 103
Crujeiras, A. B., Diaz-Lagares, A., Sandoval, J., Milagro, F. I., Navas-Carretero, S., Carreira, M. C., Gomez, A., Hervas, D., Monteiro, M. P., Casanueva, F. F., et al. (2017) · Scientific Reports · doi:10.1038/srep41903 · Cited by 103
ASGE position statement on endoscopic bariatric therapies in clinical practice
Sullivan, S. A., Kumar, N., Edmundowicz, S. A., Dayyeh, B. K. A., Jonnalagadda, S. S., Larsen, M. C., & Thompson, C. C. (2015) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2015.06.038 · Cited by 108
“Guidelines on the pharmacological management of obesity by the Endocrine Society were published in January 2015.(23) With the exception of orlistat, the obesity drugs approved for long-term use have only recently been approved by the U.”
BackgroundEmerging pharmacotherapies for obesity: A systematic review
Kokkorakis, M., Chakhtoura, M., Rhayem, C., Al Rifai, J., Ghezzawi, M., Valenzuela-Vallejo, L., & Mantzoros, C. S. (2025) · Pharmacological Reviews · doi:10.1124/pharmrev.123.001045 · Cited by 102
van Dammen, L., Wekker, V., van Oers, A. M., Mutsaerts, M. A. Q., Painter, R. C., Zwinderman, A. H., Groen, H., van de Beek, C., Muller Kobold, A. C., Kuchenbecker, W. K. H., et al. (2018) · PLOS ONE · doi:10.1371/journal.pone.0190662 · Cited by 102
“Current international guidelines state that lifestyle improvements are the cornerstone of primary prevention and treatment of obesity and cardiometabolic diseases [14, 15].”
BackgroundNakahara, D., Nan, C., Mori, K., Hanayama, M., Kikuchi, H., Hirai, S., & Egashira, Y. (2019) · European Journal of Nutrition · doi:10.1007/s00394-019-02162-7 · Cited by 110
Characterization of on-target adverse events caused by TRK inhibitor therapy
Liu, D., Flory, J., Lin, A., Offin, M., Falcon, C. J., Murciano-Goroff, Y. R., Rosen, E., Guo, R., Basu, E., Li, B. T., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.05.006 · Cited by 95
“FDA-approved medications for weight management include phentermine-topiramate, liraglutide, naltrexone-bupropion, lorcaserin, and orlistat (Table 2) [24, 25].”
BackgroundSGLT inhibitors on weight and body mass: A meta‐analysis of 116 randomized‐controlled trials
Cheong, A. J. Y., Teo, Y. N., Teo, Y. H., Syn, N. L., Ong, H. T., Ting, A. Z. H., Chia, A. Z. Q., Chong, E. Y., Chan, M. Y., Lee, C., et al. (2022) · Obesity · doi:10.1002/oby.23331 · Cited by 99
“Guidelines on obesity management recommend pharmacological management for adults with a BMI > 30 or those with a BMI > 27 with obesity- related comorbidities such as diabetes mellitus or hypertension (41).”
BackgroundFood for Thought: Reward Mechanisms and Hedonic Overeating in Obesity
Lee, P. C., & Dixon, J. B. (2017) · Current Obesity Reports · doi:10.1007/s13679-017-0280-9 · Cited by 97
Hankosky, E. R., Wang, H., Neff, L. M., Kan, H., Wang, F., Ahmad, N. N., Griffin, R., Stefanski, A., & Garvey, W. T. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15318 · Cited by 97
Treatment of Obesity in Patients With Diabetes
Bramante, C. T., Lee, C. J., & Gudzune, K. A. (2017) · Diabetes Spectrum · doi:10.2337/ds17-0030 · Cited by 92
“When possible, clinicians should attempt to reduce or find alternatives to common medications that can increase appetite and promote weight gain, including sedating antihistamines, steroids, some selective serotonin reuptake inhibitors, beta-blockers, and most antipsychotic agents (62).”
BackgroundDietary Fibre as a Unifying Remedy for the Whole Spectrum of Obesity-Associated Cardiovascular Risk
Bozzetto, L., Costabile, G., Della Pepa, G., Ciciola, P., Vetrani, C., Vitale, M., Rivellese, A. A., & Annuzzi, G. (2018) · Nutrients · doi:10.3390/nu10070943 · Cited by 93
Modern pharmacological treatment of obese patients
May, M., Schindler, C., & Engeli, S. (2020) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018819897527 · Cited by 112
Best Practices in the Management of Overweight and Obesity
Tchang, B. G., Saunders, K. H., & Igel, L. I. (2021) · Medical Clinics of North America · doi:10.1016/j.mcna.2020.08.018 · Cited by 91
The Obesity Epidemic — Understanding the Disease and the Treatment
Apovian, C. M. (2016) · New England Journal of Medicine · doi:10.1056/nejme1514957 · Cited by 92
Self-citationA Nephrologist Perspective on Obesity: From Kidney Injury to Clinical Management
García-Carro, C., Vergara, A., Bermejo, S., Azancot, M. A., Sellarés, J., & Soler, M. J. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.655871 · Cited by 101
Ndumele, C. E., Rodriguez, F., Dixon, D. L., Khan, S. S., Mukherjee, D., Bajaj, M., Bangalore, S., Bozkurt, B., Breathett, K., Clarke, S. L., et al. (2026) · JACC · doi:10.1016/j.jacc.2026.03.056 · Cited by 90
Treatment of obesity: Pharmacotherapy trends in the United States from 1999 to 2010
Xia, Y., Kelton, C. M. L., Guo, J. J., Bian, B., & Heaton, P. C. (2015) · Obesity · doi:10.1002/oby.21136 · Cited by 90
“for the treatment of patients with obesity or overweight patients with type 2 diabetes (35).”
Backgroundle Roux, C. W., Zhang, S., Aronne, L. J., Kushner, R. F., Chao, A. M., Machineni, S., Dunn, J., Chigutsa, F. B., Ahmad, N. N., & Bunck, M. C. (2023) · Obesity · doi:10.1002/oby.23612 · Cited by 91
Self-citationEffects of metformin in obesity treatment in different populations: a meta-analysis
Pu, R., Shi, D., Gan, T., Ren, X., Ba, Y., Huo, Y., Bai, Y., Zheng, T., & Cheng, N. (2020) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018820926000 · Cited by 86
Nutrition Concepts for the Treatment of Obesity in Adults
Wiechert, M., & Holzapfel, C. (2021) · Nutrients · doi:10.3390/nu14010169 · Cited by 135
“The purpose of using pharmacotherapy to manage obesity is to increase patient adherence to lifestyle changes and to overcome the biological adaptations that occur with weight loss [97].”
BackgroundSex Differences in Cardiovascular Consequences of Hypertension, Obesity, and Diabetes
Regensteiner, J. G., & Reusch, J. E. B. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.02.010 · Cited by 87
Obesity among Asian American people in the United States : A review
Li, Z., Daniel, S., Fujioka, K., & Umashanker, D. (2023) · Obesity · doi:10.1002/oby.23639 · Cited by 102
“0 with a related comorbidity, again regardless of race [1, 71, 72].”
BackgroundSuliman, M., Buckley, A., Al Tikriti, A., Tan, T., le Roux, C. W., Lessan, N., & Barakat, M. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13672 · Cited by 86
“Options for treatment of obesity include lifestyle changes, pharmacotherapy and bariatric surgery.(2,3) Recently, the glucagon-like peptide-1 (GLP-1) analogue liraglutide 3 mg has been licensed for treatment of obesity.”
BackgroundResultPrimary Care Interventions for Obesity: Review of the Evidence
Tronieri, J. S., Wadden, T. A., Chao, A. M., & Tsai, A. G. (2019) · Current Obesity Reports · doi:10.1007/s13679-019-00341-5 · Cited by 100
Multifactorial Basis and Therapeutic Strategies in Metabolism-Related Diseases
Guerra, J. V. D. S., Dias, M. M. G., Brilhante, A. J. V. C., Terra, M. F., García‐Arévalo, M., & Figueira, A. C. M. (2021) · Nutrients · doi:10.3390/nu13082830 · Cited by 112
“Other efficiency criteria are the improvement in current comorbidities, prevention of new associated diseases, and maintenance of weight loss [74,76,98].”
BackgroundMethodCurrent Knowledge of Obesity Treatment Guidelines by Health Care Professionals
Turner, M., Jannah, N., Kahan, S., Gallagher, C., & Dietz, W. (2018) · Obesity · doi:10.1002/oby.22142 · Cited by 83
“An asterisk (*) indicates prescribing practice consistent with current pharmacotherapy guidelines (12).”
BackgroundInfluentialApproach to the Patient: Management of the Post–Bariatric Surgery Patient With Weight Regain
Istfan, N. W., Lipartia, M., Anderson, W. A., Hess, D. T., & Apovian, C. M. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa702 · Cited by 83
Self-citationCrujeiras, A. B., Gómez-Arbeláez, D., Zulet, M. Á., Carreira, M. C., Sajoux, I., de Luis, D. A., Castro, A. I., Baltar, J., de la Torre, I. B., Sueiro, A. M., et al. (2017) · International Journal of Obesity · doi:10.1038/ijo.2017.138 · Cited by 87
Off-label drugs for weight management
Hendricks, E. (2017) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s95299 · Cited by 82
“Some advocates of the conventional approach now agree that off-label long-term use of phentermine is acceptable.(18) Use of the older drugs for patients with a BMI below conventional cutoffs and long-term use are two of the most common ways in which phentermine and the other older drugs are used off-label, but there a…”
He, Y., Haynes, W., Meyers, C. D., Amer, A., Zhang, Y., Mahling, P., Mendonza, A. E., Ma, S., Chutkow, W., & Bachman, E. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13654 · Cited by 81
“tion (diet and exercise) is recommended for long-term weight management in obese patients with BMI of 30 kg/m(2) and greater or of 27 kg/m(2) and greater in the presence of at least one weight-related comorbid condition such as T2DM or hypertension.(6) Reflecting the unmet medical need for new treatments for obesity,…”
BackgroundThe importance of estradiol for body weight regulation in women
Vigil, P., Meléndez, J., Petkovic, G., & Río, J. P. D. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.951186 · Cited by 98
Fastenau, J. M., Kolotkin, R. L., Fujioka, K., Alba, M., Canovatchel, W. J., & Traina, S. (2019) · Clinical Obesity · doi:10.1111/cob.12309 · Cited by 84
Real‐World Clinical Effectiveness of Liraglutide 3.0 mg for Weight Management in Canada
Wharton, S., Liu, A., Pakseresht, A., Nørtoft, E., Haase, C. L., Mancini, J., Power, G. S., Vanderlelie, S., & Christensen, R. A. G. (2019) · Obesity · doi:10.1002/oby.22462 · Cited by 77
The incretin/glucagon system as a target for pharmacotherapy of obesity
Del Prato, S., Gallwitz, B., Holst, J. J., & Meier, J. J. (2022) · Obesity Reviews · doi:10.1111/obr.13372 · Cited by 77
Current and emerging medications for overweight or obesity in people with comorbidities
Fujioka, K. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12502 · Cited by 76
“Recent recommendations for addressing overweight and obesity with or without comorbidities have been presented by the Endocrine Society [18]; the American Heart Association (AHA), American College of Cardiology (ACC) and TOS (AHA/ACC/TOS) [19]; and by the AACE and American College of Endocrinology (Figure S1) [20].”
BackgroundMethodInfluentialMedia and Its Influence on Obesity
Stanford, F. C., Tauqeer, Z., & Kyle, T. K. (2018) · Current Obesity Reports · doi:10.1007/s13679-018-0304-0 · Cited by 100
Roth, C. L., Scimia, C., Shoemaker, A. H., Gottschalk, M., Miller, J., Yuan, G., Malhotra, S., & Abuzzahab, M. J. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00087-1 · Cited by 76
Hachem, R., Assemat, G., Martins, N., Balayssac, S., Gilard, V., Martino, R., & Malet‐Martino, M. (2016) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2016.02.022 · Cited by 76
Role of glucagon-like peptide 1 receptor agonists in management of obesity
Isaacs, D., Prasad-Reddy, L., & Srivastava, S. B. (2016) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp150990 · Cited by 75
“, discontinue treatment if meaningful weight loss is not achieved after 12 weeks of therapy at the suggested maintenance dose).(6) An FDA-required Medication Guide for liraglutide includes information about the possible risks of thyroid tumors and pancreatitis with liraglutide use.”
BackgroundInfluentialChrist, J. P., & Falcone, T. (2018) · Obesity Surgery · doi:10.1007/s11695-018-3155-6 · Cited by 85
Vargas, E. J., Pesta, C. M., Bali, A., Ibegbu, E., Bazerbachi, F., Moore, R. L., Kumbhari, V., Sharaiha, R. Z., Curry, T. W., DosSantos, G., et al. (2018) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.01.046 · Cited by 75
Self-citationNijhawans, P., Behl, T., & Bhardwaj, S. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110103 · Cited by 83
Chen, Y.-K., Liu, T.-T., Teia, F. K. F., & Xie, M.-Z. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1218880 · Cited by 74
The prevalence of low muscle mass associated with obesity in the USA
Murdock, D. J., Wu, N., Grimsby, J. S., Calle, R. A., Donahue, S., Glass, D. J., Sleeman, M. W., & Sanchez, R. J. (2022) · Skeletal Muscle · doi:10.1186/s13395-022-00309-5 · Cited by 73
The Most Undertreated Chronic Disease: Addressing Obesity in Primary Care Settings
Tucker, S., Bramante, C., Conroy, M., Fitch, A., Gilden, A., Wittleder, S., & Jay, M. (2021) · Current Obesity Reports · doi:10.1007/s13679-021-00444-y · Cited by 73
Nutritional considerations for a new era: A CF foundation position paper
Leonard, A., Bailey, J., Bruce, A. S., Jia, S., Stein, A. C., Fulton, J. A., Helmick, M. J., Litvin, M., Patel, A., Powers, K. E., et al. (2023) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2023.05.010 · Cited by 84
de Freitas, L. M., & de Almeida, E. B. (2017) · Europe PMC (PubMed Central) · Cited by 113
Lundkvist, P., Pereira, M. J., Katsogiannos, P., Sjöström, C. D., Johnsson, E., & Eriksson, J. W. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12954 · Cited by 72
Badurdeen, D., Hoff, A. C., Hedjoudje, A., Adam, A., Itani, M. I., Farha, J., Abbarh, S., Kalloo, A. N., Khashab, M. A., Singh, V. K., et al. (2021) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2020.10.016 · Cited by 72
Apovian, C. M., Garvey, W. T., & Ryan, D. H. (2015) · Obesity · doi:10.1002/oby.21140 · Cited by 72
“Current treatment recommendations regarding available interventions: Balancing anticipated benefits with potential risks Current recommendations for obesity management provide a general framework for appropriate, safe, and effective implementation of available treatment options (4-6,20,21).”
BackgroundMethodInfluentialSelf-citationRecent Updates on Obesity Treatments: Available Drugs and Future Directions
Dragano, N. R. V., Fernø, J., Diéguez, C., López, M., & Milbank, E. (2020) · Neuroscience · doi:10.1016/j.neuroscience.2020.04.034 · Cited by 85
Carmina, E., & Longo, R. A. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12185921 · Cited by 97
“The mean weight loss observed after treatment with semaglutide was larger than that reported with metformin [2,7,8] or liraglutide [9–12] and was obtained using low doses of the product with very few side effects.”
BackgroundLong-term effects of weight-reducing drugs in people with hypertension
Siebenhofer, A., Winterholer, S., Jeitler, K., Horvath, K., Berghold, A., Krenn, C., & Semlitsch, T. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007654.pub5 · Cited by 70
Persistence of newer anti-obesity medications in a real-world setting
Ganguly, R., Tian, Y., Kong, S. X., Hersloev, M., Hobbs, T., Smolarz, B. G., Ramasamy, A., Haase, C. L., & Weng, W. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.07.017 · Cited by 68
Bays, H. E., Fitch, A., Christensen, S., Burridge, K., & Tondt, J. (2022) · Obesity Pillars · doi:10.1016/j.obpill.2022.100018 · Cited by 68
Ndumele, C. E., Rodríguez, F., Dixon, D. L., Khan, S. S., Mukherjee, D., Bajaj, M. S., Bangalore, S., Bozkurt, B., Breathett, K. K., Clarke, S. L., et al. (2026) · Circulation · doi:10.1161/cir.0000000000001453 · Cited by 160
Treatment Approach to Patients With Severe Insulin Resistance
Church, T., & Haines, S. T. (2016) · Clinical Diabetes · doi:10.2337/diaclin.34.2.97 · Cited by 76
“GLP-1 receptor agonists, although not as potent as U-500 regular insulin in terms of A1C reduction, are an attractive alternative for obese patients with severe insulin resistance (53).”
BackgroundVerhaegen, A. A., & Gaal, L. F. V. (2017) · Journal of Endocrinological Investigation · doi:10.1007/s40618-017-0719-6 · Cited by 87
Effectiveness and safety of drugs for obesity
Henderson Lewis, K., Sloan, C. E., Bessesen, D. H., & Arterburn, D. (2024) · BMJ · doi:10.1136/bmj-2022-072686 · Cited by 66
“In light of the multiple neuroendocrine pathways governing body weight and appetite, 11 a single agent pharmacotherapy approach is likely inadequate to support durable, clinically significant weight loss for all patients.”
BackgroundSelf-citationKushner, R. F., & Kahan, S. I. (2018) · Medical Clinics of North America · doi:10.1016/j.mcna.2017.08.003 · Cited by 86
“Most notable are the American Heart Association/American College of Cardiology/The Obesity Society Guideline for the Management of Overweight and Obesity in Adults,(27) The American Society of Clinical Endocrinologists (AACE) and the American College of Endocrinology (ACE) Clinical Practice Guidelines for Comprehensiv…”
BackgroundAlamuddin, N., Bakizada, Z. M., & Wadden, T. A. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.66.8806 · Cited by 74
Liraglutide 3.0 mg for Weight Management: A Population Pharmacokinetic Analysis
Overgaard, R. V., Petri, K. C., Jacobsen, L. V., & Jensen, C. B. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-016-0410-7 · Cited by 64
The Saudi clinical practice guideline for the management of overweight and obesity in adults
Alfadda, A. A., Al-Dhwayan, M. M., Alharbi, A. A., Khudhair, B. K. A., Nozha, O. M. A., Al-Qahtani, N. M., Alzahrani, S. H., Bardisi, W. M., Sallam, R. M., Riva, J. J., et al. (2016) · Saudi Medical Journal · doi:10.15537/smj.2016.10.14353 · Cited by 64
What is the role of bariatric surgery in the management of obesity?
Panteliou, E., & Miras, A. D. (2017) · Climacteric · doi:10.1080/13697137.2017.1262638 · Cited by 76
Obesity: Scope, Lifestyle Interventions, and Medical Management
McCafferty, B. J., Hill, J. O., & Gunn, A. J. (2020) · Techniques in vascular and interventional radiology · doi:10.1016/j.tvir.2020.100653 · Cited by 84
Temporal discounting as a candidate behavioral marker of obesity
Bickel, W. K., Lemos, R. F., Tomlinson, D. C., Craft, W. H., Keith, D. R., Athamneh, L. N., Basso, J. C., & Epstein, L. H. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.07.035 · Cited by 79
Maffeis, C., Olivieri, F., Valerio, G., Verduci, E., Licenziati, M. R., Calcaterra, V., Pelizzo, G., Salerno, M., Staiano, A., Bernasconi, S., et al. (2023) · Italian Journal of Pediatrics · doi:10.1186/s13052-023-01458-z · Cited by 65
“Through reduction of norepinephrine reuptake, it stimulates pro-opiomelanocortin (POMC) neurons in hypothalamus [114]; additionally, it improves appetite inhibitory control on prefrontal cortex by acting on serotonin and dopamine reuptake [115, 116].”
BackgroundSajoux, I., Lorenzo, P. M., Gomez-Arbelaez, D., Zulet, M. A., Abete, I., Castro, A. I., Baltar, J., Portillo, M. P., Tinahones, F. J., Martinez, J. A., et al. (2019) · Nutrients · doi:10.3390/nu11102368 · Cited by 63
Tsai, A. G., & Bessesen, D. H. (2019) · Annals of Internal Medicine · doi:10.7326/aitc201903050 · Cited by 83
Self-citation
Metadata
- Authors
- Apovian, C. M., Aronne, L. J., Bessesen, D. H., McDonnell, M. E., Murad, M. H., Pagotto, U., Ryan, D. H., & Still, C. D.
- Affiliations
- Pennington Biomedical Research Center (US)
- Cornell University (US)
- Denver Health Medical Center (US)
- Brigham and Women's Hospital (US)
- Mayo Clinic (US)
- IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola (IT)
- Geisinger Health System (US)
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2015-02
- Volume
- 100
- Issue
- 2
- Pages
- 342-362
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2109366467
- Semantic Scholar
- 32e063efbad03793d5b9794138fe9a8f9b3a4650
- Cited by
- 1,347
- References
- 154
- Citations by year
- 2026: 109 · 2025: 128 · 2024: 157 · 2023: 134 · 2022: 112 · 2021: 129 · 2020: 132 · 2019: 98 · 2018: 91 · 2017: 102 · 2016: 95 · 2015: 55
- FWCI
- 82.37
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion, cc-by-nc-nd)
- INFM-OAR (INFN Catania) (submittedVersion, other-oa)
- Zenodo (CERN European Organization for Nuclear Research) (cc-by)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Obesity, Physical Activity, Diet
- Keywords
- obesity, anti-obesity drugs, weight loss, lifestyle modification, obesity-related comorbidities, medication-induced weight gain, drug prescribing, chronic disease medications
- MeSH terms
- Endocrinology, Humans, Obesity, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.